Glaucoma Evaluation and Management in Eyes with Boston Type 1 and Aurolab Keratoprostheses in an Indian Cohort
- PMID: 36197336
- DOI: 10.1097/ICO.0000000000003132
Glaucoma Evaluation and Management in Eyes with Boston Type 1 and Aurolab Keratoprostheses in an Indian Cohort
Conflict of interest statement
Financial disclosures/conflicts of interest: None reported.
Comment in
-
Reply.Cornea. 2022 Dec 1;41(12):e26. doi: 10.1097/ICO.0000000000003133. Epub 2022 Sep 28. Cornea. 2022. PMID: 36343170 No abstract available.
Comment on
-
Glaucoma Evaluation and Management in Eyes With Boston Type 1 and Aurolab Keratoprostheses in an Indian Cohort.Cornea. 2022 May 1;41(5):552-561. doi: 10.1097/ICO.0000000000002986. Cornea. 2022. PMID: 35383615
References
-
- Senthil S, Mohamed A, Shanbhag SS, et al. Glaucoma evaluation and management in eyes with Boston type 1 and Aurolab Keratoprostheses in an Indian cohort. Cornea. 2022;41:552–561.
-
- Basu S, Serna-Ojeda JC, Senthil S, et al. The Aurolab keratoprosthesis (KPro) versus the Boston type I KPro: 5-year clinical outcomes in 134 cases of bilateral corneal blindness. Am J Ophthalmol. 2019;205:175–183.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
